Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Lysosomal Storage Diseases
1.2.3 Diabetes
1.2.4 Obesity
1.2.5 Inherited Metabolic Disorders
1.2.6 Hypercholesterolemia
1.3 Market by Application
1.3.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorder Therapeutics Market Perspective (2017-2028)
2.2 Metabolic Disorder Therapeutics Growth Trends by Region
2.2.1 Metabolic Disorder Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Metabolic Disorder Therapeutics Market Dynamics
2.3.1 Metabolic Disorder Therapeutics Industry Trends
2.3.2 Metabolic Disorder Therapeutics Market Drivers
2.3.3 Metabolic Disorder Therapeutics Market Challenges
2.3.4 Metabolic Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2021
3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorder Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2023-2028)
5 Metabolic Disorder Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2017-2028)
6.2 North America Metabolic Disorder Therapeutics Market Size by Type
6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
6.3 North America Metabolic Disorder Therapeutics Market Size by Application
6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
6.4 North America Metabolic Disorder Therapeutics Market Size by Country
6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2017-2028)
7.2 Europe Metabolic Disorder Therapeutics Market Size by Type
7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Application
7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Country
7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type
8.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application
8.3.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region
8.4.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metabolic Disorder Therapeutics Market Size (2017-2028)
9.2 Latin America Metabolic Disorder Therapeutics Market Size by Type
9.2.1 Latin America Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Metabolic Disorder Therapeutics Market Size by Application
9.3.1 Latin America Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country
9.4.1 Latin America Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type
10.2.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application
10.3.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country
10.4.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Details
11.1.2 Novo Nordisk A/S Business Overview
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.1.5 Novo Nordisk A/S Recent Developments
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Details
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.2.5 Sanofi S.A. Recent Developments
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Details
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.3.5 Boehringer Ingelheim GmbH Recent Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.4.5 Eli Lilly and Company Recent Developments
11.5 Merck KgaA
11.5.1 Merck KgaA Company Details
11.5.2 Merck KgaA Business Overview
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.5.5 Merck KgaA Recent Developments
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Details
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.6.5 Amgen, Inc. Recent Developments
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Details
11.7.2 AstraZeneca PLC Business Overview
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.7.5 AstraZeneca PLC Recent Developments
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Details
11.8.2 Actelion Pharmaceuticals Ltd. Business Overview
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.8.5 Actelion Pharmaceuticals Ltd. Recent Developments
11.9 Shire PLC
11.9.1 Shire PLC Company Details
11.9.2 Shire PLC Business Overview
11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.9.5 Shire PLC Recent Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Details
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.10.5 AbbVie, Inc. Recent Developments
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Details
11.11.2 Biocon Ltd. Business Overview
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.11.5 Biocon Ltd. Recent Developments
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Details
11.12.2 BioMarin Pharmaceutical, Inc. Business Overview
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.12.5 BioMarin Pharmaceutical, Inc. Recent Developments
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Details
11.13.2 Bristol-Myers Squibb Company Business Overview
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.13.5 Bristol-Myers Squibb Company Recent Developments
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Details
11.14.2 Cipla, Inc. Business Overview
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.14.5 Cipla, Inc. Recent Developments
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Details
11.15.2 CymaBay Therapeutics, Inc. Business Overview
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
11.15.5 CymaBay Therapeutics, Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer